Celldex Therapeutics, Inc. (FRA:TCE2)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.04B +70.7% |
| Revenue (ttm) | 750.22K -88.6% |
| Net Income | -246.01M |
| EPS | -3.70 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 24.50 |
| Previous Close | 25.49 |
| Day's Range | 24.50 - 24.50 |
| 52-Week Range | 16.90 - 29.22 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,... [Read more]
Financial Performance
In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Celldex Therapeutics Slides: Corporate presentation
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Celldex price target raised to $54 from $38 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Celldex (CLDX) to $54 from $38 and keeps an Overweight rating on the shares. The firm is getting more…
Celldex price target raised to $38 from $34 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Celldex (CLDX) to $38 from $34 and keeps a Neutral rating on the shares.
Celldex price target raised to $48 from $45 at Barclays
Barclays raised the firm’s price target on Celldex (CLDX) to $48 from $45 and keeps an Overweight rating on the shares.
Celldex sees funds sufficient to fund current planned operations through 2028
Celldex (CLDX) believes that the cash, cash equivalents and marketable securities at March 31, along with the approximately $323.9M in net proceeds from its April underwritten public offering, are suf...
Celldex Reports First Quarter Financial Results and Provides Corporate Update
HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.
Celldex Therapeutics Earnings release: Q1 2026
Celldex Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Celldex Therapeutics Quarterly report: Q1 2026
Celldex Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Celldex Therapeutics Proxy statement: Proxy filing
Celldex Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)
Celldex stock was on the move Monday alongside an upgrade and increased price target from a top Wall Street analyst.
Celldex upgraded to Overweight from Underweight at Barclays
Barclays upgraded Celldex (CLDX) to Overweight from Underweight with a price target of $45, up from $24. The firm has conviction in a successful Phase 3 readout in chronic spontaneous…
Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Barzolvolimab demonstrates rapid, durable, and high complete response rates in urticaria, with phase III data expected in Q4. Positioned for both first- and second-line advanced therapy markets, the company is well-funded and advancing a promising pipeline, including CDX-622.
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Vi...
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public off...
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 sh...
Celldex announces common stock offering, no amount given
Celldex (CLDX) Therapeutics announced that it has commenced an underwritten public offering for the sale of shares of its common stock. Celldex currently intends to use the net proceeds of…
Celldex Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the s...
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
Celldex (CLDX) presented additional data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria and cold urticaria and symptomatic dermographism demonstrating pro...
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life - - Data further d emonstrates first-in-class and best-in-disease barzolvolimab profile -
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Celldex (CLDX) to Outperform from Peer Perform with a $44 price target The firm sees a better catalyst setup for the shares in 2026 relative to 2025.
Celldex Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Phase III CSU and CIndU studies showed unprecedented efficacy and rapid enrollment, with barzolvolimab positioned for both frontline and advanced therapy in severe urticaria. Key data readouts are expected for PN in summer, CSU in Q4, and atopic dermatitis by year-end.
Celldex Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Multiple late-stage trials have completed enrollment, with key data readouts for PN, CSU, and AD expected this year. Barzolvolimab is positioned for frontline and second-line use in CSU, with commercial plans for pre-filled syringes and auto-injectors. The bispecific program advances with new asthma studies and upcoming data.
Celldex price target raised to $34 from $30 at Goldman Sachs
Goldman Sachs analyst Richard Law raised the firm’s price target on Celldex (CLDX) to $34 from $30 and keeps a Neutral rating on the shares. Celldex is entering a catalyst-rich…
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
Celldex (CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension, highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after sy...
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved qu...